Longitudinal Clinical Observation of a Digital Twin Model for Blastocyst Evaluation in IVF Clinics

This observational study collects and integrates multimodal, non-image data from routine IVF cycles to construct digital twin models of human blastocysts. The dataset includes synchronized molecular, cellular, biochemical, and clinical parameters describing both the embryo and the maternal environment during implantation and early pregnancy. All information is fully de-identified and obtained as part of standard clinical care.

Parental and Clinical Background

The dataset incorporates:

demographic factors, reproductive history, and relevant risk factors;

karyotype results, thrombophilia and autoimmune screening;

sperm DNA fragmentation indices;

ovarian stimulation parameters and hormonal dynamics throughout the IVF cycle.

IVF Laboratory Data

Non-image embryologic information includes:

oocyte maturity and fertilization method (e.g., ICSI);

early cleavage development documented in descriptive text format (no images or videos);

blastocyst grading;

preimplantation genetic testing for aneuploidy (PGT-A), including ploidy status and mosaicism.

Molecular and Secretome Data

Embryo- and culture-media-associated biomarkers include:

cytokines, growth factors, LIF, and metabolic indicators in spent media;

exosomal microRNA signatures linked to implantation potential;

transcriptomic and methylation profiles of trophectoderm samples when available.

Endometrial and Immune Environment

Maternal environment assessment includes:

transcriptomic profiling of the endometrial receptivity window (ERA-like signatures);

uterine immune parameters such as uNK cell activity and T-regulatory balance.

Pregnancy, Delivery, and Child Follow-Up

Collected follow-up information includes:

β-hCG kinetics, early ultrasound development, and pregnancy complications;

delivery outcomes and newborn characteristics;

longitudinal developmental assessments of the child up to 3 years of age.

Study Objectives

To construct digital twin representations of individual blastocysts by integrating multi-omics and clinical parameters obtained during IVF.

To identify non-invasive biomarkers of implantation success and embryo viability.

To analyze associations between early embryo molecular profiles and neonatal or early childhood developmental outcomes.

Study Design

This is a non-interventional, observational study. All data are obtained retrospectively and/or prospectively from routine clinical practice in IVF clinics. No experimental procedures, investigational drugs, or investigational devices are introduced. Participation involves only the use of fully de-identified clinical, laboratory, and follow-up data for research purposes. Parents provide informed consent for use of de-identified information.

The study is not conducted under an IND or IDE, and it does not involve FDA-regulated products.

Significance

The resulting longitudinal dataset will support the development of AI-based digital twin models, facilitate biomarker discovery, and advance precision reproductive medicine. These models aim to predict blastocyst competence, implantation potential, and early developmental trajectories using non-image, multimodal clinical and molecular data.

Inclusion criteria

• Women undergoing in vitro fertilization (IVF) treatment at participating fertility clinics.
• Availability of non-image embryo development data.
• Availability of text-based morphological embryo descriptions.
• Availability of PGT-A results.
• Availability of secretome and exosomal biomarker data.
• Availability of molecular and biochemical data collected during routine clinical care.
• Availability of IVF cycle parameters collected during routine clinical workflow.
• Embryos evaluated according to standard clinic protocols with documented implantation outcomes.
• Age of the oocyte provider between 20 and 42 years.
• Signed informed consent allowing use of fully de-identified clinical, laboratory, molecular, and follow-up data.

Exclusion criteria

• Embryos lacking sufficient non-image developmental data required for digital twin generation or implantation outcome assessment.
• Use of donor oocytes or donor embryos when linkage with required clinical or laboratory metadata is not possible.
• Cases in which implantation outcome cannot be confirmed.
• Presence of severe uterine abnormalities prior to embryo transfer that may affect implantation reliability.
• Withdrawal of consent for use of anonymized clinical, laboratory, or follow-up data.